Open AccessRetinoic Acid-Loaded Poly(lactic-co-glycolic acid) Nanoparticle Formulation of ApoB-100-Derived Peptide 210 Attenuates Atherosclerosis
Author(s) -
Xin Yi,
Ying Wang,
Zhenquan Jia,
Sylvia Hiller,
Jun Nakamura,
J. Christopher Luft,
Shaomin Tian,
Joseph M. DeSimone
Publication year - 2020
Publication title -
journal of biomedical nanotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.558
H-Index - 75
eISSN - 1550-7041
pISSN - 1550-7033
DOI - 10.1166/jbn.2020.2905
Subject(s) - plga , adjuvant , retinoic acid , immune system , chemistry , autoantibody , apolipoprotein b , nanoparticle , inflammation , materials science , medicine , immunology , nanotechnology , cholesterol , biochemistry , antibody , gene
We developed a vaccine formulation containing ApoB derived P210 peptides as autoantigens, retinoic acid (RA) as an immune enhancer, both of which were delivered using PLGA nanoparticles. The formula was used to induce an immune response in 12-week-old male Apoe -/- mice with pre-existing atherosclerotic lesions. The nanotechnology platform PRINT ® was used to fabricate PLGA nanoparticles that encapsulated RA inside and adsorbed the P210 onto the particle surface. In this study, we demonstrated that immunization of Apoe -/- mice with the formulation was able to considerably attenuate atherosclerotic lesions, accompanied by increased P210 specific IgM and another oxidized lipid derived autoantigen, M2AA, specific IgG autoantibodies, and decreased the inflammatory response, as compared to the P210 group with Freund's adjuvant. Our formulation represents an exciting technology to enhance the efficacy of the P210 vaccine.